177Lu–PSMA-617 is a radioligand therapy targeting prostate-specific membrane antigen (PSMA), a highly expressed protein on the surface of prostate adenocarcinoma cells (14). This evidence concerns the gene FOLH1 and prostate adenocarcinoma.